Results 101 to 110 of about 64,955 (112)

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Journal of Clinical Oncology, 2005
Vladimir Semiglazov, Tadeusz Pienkowski
exaly  

Physico-chemical properties and thermal stability of microcrystalline cellulose isolated from Alfa fibres

Carbohydrate Polymers, 2014
Djalal Trache, Kamel Khimeche, Nicolas Brosse   +2 more
exaly  

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

New England Journal of Medicine, 2002
Michael W Fried, K Rajender Reddy, Dieter Häussinger   +2 more
exaly  

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial

Lancet, The, 2007
Simon Nadel, Mark John Peters
exaly  

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Journal of Clinical Oncology, 2009
Robert J Motzer, Thomas E Hutson, C?zary A Szczylik   +2 more
exaly  

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Lancet, The, 2023
exaly  

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study

Lancet Infectious Diseases, The, 2014
Ali S Omrani, Kamran Baig, Ziad Ahmed Memish   +2 more
exaly  

P134 Efficacy and safety of 48-week off-therapy of Bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204

P134 Efficacy and safety of 48-week off-therapy of Bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204
T. Asselah, V. Chulanov, P. Lampertico, H. Wedemeyer, A. Streinu-Cercel, V. Pantea, Stefan Lazar, G. Gherlan, P. Bogomolov, Tatyana V. Stepanova, V. Morozov, Vladimir Syutkin, O. Sagalova, D. Manuilov, Renee-Claude Mercier, Lei Ye, Grace M. Chee, Ben L. Da, Audrey H. Lau, A. Osinusi, M. Bourliere, Vlad Ratziu, Stanilas Pol, M.N. Hilleret, Fabien Zoulim   +24 more
semanticscholar   +1 more source

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Lancet, The, 2001
exaly  

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

The Lancet Gastroenterology and Hepatology, 2017
Valentin Cebotarescu, Lilia Cojuhari, Emmanuel Gordien   +2 more
exaly